Abstract
We report here on the preliminary treatment findings of a CCLSG NHL 960 study that was initiated in March 1996. In this study, 37 patients with non-Hodgkin's lymphoma were assigned to 4 different treatment groups according to disease stage and histology: (1) localized disease; (2) advanced disease, lymphoblastic type; (3) advanced disease, large cell type; and (4) advanced disease, Burkitt type. The first three groups received the modified protocols of the NHL 890 study. Groups 1 and 3 received COPADM induction therapy (CPM, VCR, PRD, ADR, and MTX). After achieving remission, Group 1 received only maintenance therapy consisting of alternate administration of 7 drugs, while Group 3 received additional intensification therapy with combination chemotherapy consisting of MTX and Ara-C, followed by a maintenance phase involving the administration of 9 drugs. Group 2 received COPADL induction therapy (CPM, VCR, PRD, ADR, and LASP) and consolidation/intensification therapies followed by a maintenance phase. Group 4 received short-term intensive COPADM polychemotherapy. Twelve patients with localized with localized disease (stage I-II) and 25 patients with advanced disease (stage III-IV) were enrolled in this study. Except for 2 patients in the advanced disease stages who died earlier in the course of the study, all patients remained in remission.
Publication types
-
Clinical Trial
-
English Abstract
-
Multicenter Study
MeSH terms
-
Adolescent
-
Anti-Inflammatory Agents / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Burkitt Lymphoma / drug therapy
-
Child
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Hydrocortisone / administration & dosage
-
Infant
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Male
-
Methotrexate / administration & dosage
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Prednisolone / administration & dosage
-
Remission Induction
-
Vincristine / administration & dosage
Substances
-
Anti-Inflammatory Agents
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Hormonal
-
Antineoplastic Agents, Phytogenic
-
Cytarabine
-
Vincristine
-
Etoposide
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
Asparaginase
-
Hydrocortisone
-
Methotrexate
-
Daunorubicin